AXON ENTERPRISE, INC. annual report, FY2023

Axon Enterprise, Inc. Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2023. Although the request references 2023 Q4, this filing is an annual report; it includes selected fourth-quarter information but primarily compares full-year 2023 with 2022.

Business Context

Axon provides law-enforcement technology through two reportable segments: TASER, including conducted-energy devices, cartridges, warranties and training; and Software and Sensors, including body-worn and in-car cameras, Axon Evidence cloud software, productivity and real-time operations software, and related services.

Annual recurring revenue was $697 million at December 31, 2023. The company had approximately 3,330 full-time employees and 930 temporary employees. No customer represented more than 10% of annual sales.

Key Financial Metrics

Metric	2023	2022	Change
Net sales	$1.563 billion	$1.190 billion	31.4% increase
Product sales	$967.7 million	$801.4 million	20.8% increase
Service sales	$595.7 million	$388.5 million	53.3% increase
Gross margin	$955.4 million; 61.1%	$728.6 million; 61.2%	Margin down 0.1 point
Income from operations	$154.8 million; 9.9%	$93.3 million; 7.8%	66.0% increase
Net income	$174.2 million	$147.1 million	18.4% increase
Diluted EPS	$2.31	$2.03	13.8% increase
Adjusted EBITDA	$329.3 million	$232.3 million	41.8% increase
Operating cash flow	$189.3 million	$235.4 million	19.6% decrease

Revenue and Segment Performance

Software and Sensors: Revenue increased 44.4% to $950.8 million, driven primarily by Axon Evidence and cloud services, higher users and revenue per user, Fleet systems, and Body cameras.
TASER: Revenue increased 15.2% to $612.6 million, led by professional TASER devices and cartridges. TASER 10 began shipping in the first quarter of 2023.
Axon Evidence and cloud services: Combined revenue across segments was $601.0 million, compared with $390.6 million in 2022.
Fourth quarter: Revenue was $432.1 million, up 4.5% from the third quarter. Software and Sensors revenue increased 7.9% sequentially, while TASER revenue declined 0.8%, primarily because of lower international cartridge volume.

Cash, Liquidity and Debt

Cash and cash equivalents were $598.5 million at year-end, compared with $353.7 million in 2022.
Cash, cash equivalents and available-for-sale investments totaled approximately $1.2 billion.
Net cash provided by investing activities was $12.5 million, including $59.5 million of capital expenditures and $37.3 million for acquisitions and strategic investments.
The company had $690.0 million principal amount of 0.50% convertible senior notes due December 2027; the carrying amount was $677.1 million.
A $200.0 million revolving credit facility had no borrowings outstanding and $192.5 million available after letters of credit. The net leverage ratio was 0.10 to 1.00 and interest coverage was 45.61 to 1.00.
Contractual obligations totaled $1.559 billion, including $780.7 million of purchase obligations and $703.4 million of convertible-note principal and interest.

Material Changes Versus 2022

Revenue growth accelerated, with Software and Sensors becoming a larger share of total sales: 60.8% in 2023 versus 55.3% in 2022.
Service revenue increased to 38.1% of sales from 32.7%, reflecting continued movement toward subscriptions and recurring cloud services.
Operating margin improved to 9.9% from 7.8%, despite operating expenses increasing 26.0% to $800.6 million.
Operating cash flow declined despite higher net income, primarily because accounts receivable and contract assets, prepaid expenses, and inventory increased substantially.
Other income changed from a $99.0 million gain in 2022 to a $41.9 million loss in 2023. The 2023 result included an $80.5 million net unrealized loss on strategic investments and related warrants, partially offset by a $38.7 million unrealized gain on marketable securities associated with Cellebrite.
The effective tax rate was a benefit of 12.4% in 2023 versus an expense rate of 25.1% in 2022, largely due to excess stock-based compensation benefits and R&D credits.
Warranty expense increased to $8.1 million from $0.2 million, and the warranty reserve rose to $7.4 million, primarily related to TASER 7 claims and a production issue.
The company raised $94.7 million of net proceeds through its at-the-market equity offering and issued additional shares, creating potential dilution.
A material weakness in revenue recognition and deferred-revenue controls identified in 2022 was reported as remediated as of December 31, 2023. Management and the independent auditor concluded that internal control over financial reporting was effective.

Guidance, Outlook and Management Commentary

The filing does not provide a clear formal full-year 2024 revenue or earnings guidance figure.
Management expects to recognize approximately 15% to 25% of the $7.1 billion remaining performance obligation balance over the next 12 months, with the remainder generally recognized over the following ten years. Actual recognition remains subject to deployment delays, budget appropriations and cancellation provisions.
Management expects available cash, investments, operating cash flow and credit capacity to fund anticipated requirements for at least the next 12 months.
Growth priorities include expanding recurring cloud software, increasing users and connected devices, expanding direct sales and international operations, and investing in new products including TASER 10, Body 4, Fleet, AI, drones and real-time operations technologies.
January 2024 subsequent event: Axon acquired the remaining outstanding stock of Fusus for $240.0 million, subject to customary adjustments. The acquisition accounting was not complete when the filing was prepared.

Key Risks, Contingencies and Unusual Items

Demand depends heavily on law-enforcement and government budgets, political priorities, appropriations, open bidding and contract-renewal decisions. Certain contracts permit termination for convenience or non-appropriation.
Subscription growth increases deferred revenue, contract assets and receivables and may delay cash collection relative to upfront hardware sales.
Cybersecurity, data privacy, cloud-service availability and loss or corruption of digital evidence could result in customer loss, litigation, regulatory penalties and reputational damage. The company reported no known cybersecurity incident that had materially affected it, but identified ongoing threats that could materially affect the business if realized.
TASER 10 is regulated as a firearm by the ATF for U.S. domestic sales, creating additional licensing, compliance, supply-chain and market-access risks.
The company faces product-liability litigation, including five lawsuits alleging wrongful death or personal injury involving TASER devices. Management stated that material losses were not reasonably possible based on information available at year-end, but litigation outcomes remain uncertain.
A purported class action relating to the Vievu acquisition and alleged antitrust violations remained pending after the FTC dismissed its administrative complaint in October 2023.
The company had a $425.0 million cloud-hosting commitment, with $338.8 million remaining at year-end, and approximately $429.5 million of open purchase orders.
Stock-based compensation was $131.4 million in 2023, and additional employee RSUs granted in January 2024 are expected to increase future compensation expense.
Most cash balances were held at two depository institutions, with $560.4 million subject to uninsured-deposit exposure.

Most Important Facts for Investors to Verify

Whether Software and Sensors growth, cloud revenue and annual recurring revenue continue to offset potential variability in TASER demand.
Conversion of the $7.1 billion remaining performance obligation balance into recognized revenue and cash, including the effects of customer appropriations, deployment timing and cancellations.
Operating cash-flow conversion, accounts receivable, contract assets, deferred revenue and inventory as subscription sales continue to expand.
Gross-margin trends, particularly the recovery of TASER margins after TASER 7 warranty costs and the manufacturing ramp for TASER 10.
The financial impact and integration progress of the $240.0 million Fusus acquisition.
Potential dilution from the convertible notes, warrants, stock-based compensation and the ATM equity offering.
Developments in product-liability and antitrust litigation, TASER 10 regulatory compliance, cybersecurity, privacy and AI-related regulation.
Whether the remediation of the prior revenue-recognition control weakness remains effective as operations and contract complexity increase.